OGN
Organon·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Sell"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OGN
Organon & Co.
A pharmaceutical company that specializes in the field of reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia
30 Hudson Street, Floor 33, Jersey City, New Jersey, 07302
--
Organon & Co., a Delaware corporation, was incorporated on March 11, 2020. Organon is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a range of prescription therapies targeting women's health, biosimilars and well-known brands. Their mission is to be the world's leading women's healthcare company, providing better and healthier services to every woman every day. They plan to use their strengths in reproductive health to build a range of health solutions for women from adolescence to menopause and beyond.
Earnings Call
Q1/2025
Estimate EPS0.89
Actual EPS1.02
Estimate Revenue1.51B
Actual Revenue1.51B
Contradictions Unveiled: Organon's Q1 2025 Earnings Call Reveals Tensions in Deleveraging, M&A, and Dividend Strategies
May 13,2025 11:09
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.94
Actual EPS1
Estimate Revenue1.56B
Actual Revenue1.59B
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts
Aug 14,2025 07:50
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.93
Actual EPS1.01
Estimate Revenue1.58B
Actual Revenue1.60B
Organon's Q3 2025 Earnings Call: Contradictions Emerge on Vtama Growth, Divestiture Strategy, and Nexplanon Sales Dynamics
Nov 10,2025 11:00
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
OGN has released its 2025 Q3 earnings. EPS was reported at 1.01, versus the expected 0.93, beating expectations. The chart below visualizes how OGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OGN has released its 2025 Q3 earnings report, with revenue of 1.60B, reflecting a YoY change of 1.26%, and net profit of 160.00M, showing a YoY change of -55.43%. The Sankey diagram below clearly presents OGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
